| Dr Leslie Gamache, MD | |
|
1601 E 19th Ave Ste 4350, Suite 454, Denver, CO 80218-1253 | |
| (303) 228-1240 | |
| (303) 228-1250 |
| Full Name | Dr Leslie Gamache |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 23 Years |
| Location | 1601 E 19th Ave Ste 4350, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851303002 | NPI | - | NPPES |
| 10025716100 | Medicaid | NE | |
| 1851303002 | Medicaid | WY | |
| 200739320A | Medicaid | KS | |
| 50858360 | Medicaid | NM | |
| 89438825 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 44771 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presbyterian St Luke's Medical Center | Denver, CO | Hospital |
| Rose Medical Center | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthone Clinic Services - Medical Specialties Llc | 1850480807 | 24 |
News Archive
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
The New York Times reports that young people — representing nearly one-third of the 46 million uninsured in America — stand to "reap substantial benefits" from expanded coverage for them in the new health law.
In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.
The Washington Post reports on an event hosted last week by Washington Post Live, the division of the newspaper that organizes forums and debates, which brought together a number of attendees of the U.N. summit on non-communicable diseases (NCDs) wrapping up today in New York, as well as other key thinkers on global health, to discuss curbing the rise of NCDs.
› Verified 2 days ago
| Entity Name | Healthone Clinic Services - Medical Specialties Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457549461 PECOS PAC ID: 1850480807 Enrollment ID: O20071129000065 |
News Archive
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
The New York Times reports that young people — representing nearly one-third of the 46 million uninsured in America — stand to "reap substantial benefits" from expanded coverage for them in the new health law.
In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.
The Washington Post reports on an event hosted last week by Washington Post Live, the division of the newspaper that organizes forums and debates, which brought together a number of attendees of the U.N. summit on non-communicable diseases (NCDs) wrapping up today in New York, as well as other key thinkers on global health, to discuss curbing the rise of NCDs.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leslie Gamache, MD 4900 S Monaco St, Suite 210, Denver, CO 80237-3486 Ph: (303) 228-1240 | Dr Leslie Gamache, MD 1601 E 19th Ave Ste 4350, Suite 454, Denver, CO 80218-1253 Ph: (303) 228-1240 |
News Archive
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
The New York Times reports that young people — representing nearly one-third of the 46 million uninsured in America — stand to "reap substantial benefits" from expanded coverage for them in the new health law.
In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.
The Washington Post reports on an event hosted last week by Washington Post Live, the division of the newspaper that organizes forums and debates, which brought together a number of attendees of the U.N. summit on non-communicable diseases (NCDs) wrapping up today in New York, as well as other key thinkers on global health, to discuss curbing the rise of NCDs.
› Verified 2 days ago
Katrina Wagoner-hursh, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |